fashion -WSS

fashion

author：fashion 2025-08-31 02:02:22 - browse：14885

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： First Opinion Podcast: Long Covid needs a new approach

WSS

The explosion of genetic testing requires a new approach

UnitedHealth’s board chair also owns a personal investment firm

Researchers explore possible ties between long Covid, menopause

Can CDC director Mandy Cohen drive consensus in Washington?

The explosion of genetic testing requires a new approach

Who gets to use the title 'doctor'?

focus

fashion

Wikipedia

What does generative AI mean for health care? We asked experts

Lawmakers consider Medicare pay reforms for doctors

Drug repurposing or repositioning? The language matters

Federal judge rules Oregon’s tough new gun law is constitutional

Medical records are filled with copy

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Malaria cases in Florida and Texas: Here’s what you need to know

UnitedHealth’s board chair also owns a personal investment firm

Bright Health sells Medicare Advantage business to Molina

Senate committee scrutinizes Medicare Advantage brokers

explore

CEOs share strategies for surviving biotech slump

Celiac disease study examines precisely how gluten triggers injury

Care demand spikes challenge UnitedHealth’s provider arm

Who gets to use the title 'doctor'?

How climate

Beam Therapeutics to lay off 20% of its staff, re

leisure time

entertainment

explore

hotspot